Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

BPTH

Bio Path (BPTH)

Bio Path Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BPTH
DateTimeSourceHeadlineSymbolCompany
24/05/202421:00GlobeNewswire Inc.Bio-Path Holdings to Present Data at 2024 European Hematology Association CongressNASDAQ:BPTHBio Path Holdings Inc
24/05/202407:00GlobeNewswire Inc.Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:BPTHBio Path Holdings Inc
15/05/202421:50IH Market NewsU.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices DropNASDAQ:BPTHBio Path Holdings Inc
15/05/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
15/05/202421:00GlobeNewswire Inc.Bio-Path Holdings Reports First Quarter 2024 Financial ResultsNASDAQ:BPTHBio Path Holdings Inc
15/05/202406:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BPTHBio Path Holdings Inc
08/05/202421:00GlobeNewswire Inc.Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024NASDAQ:BPTHBio Path Holdings Inc
20/04/202402:14GlobeNewswire Inc.Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:BPTHBio Path Holdings Inc
19/04/202403:57GlobeNewswire Inc.Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:BPTHBio Path Holdings Inc
18/04/202421:00GlobeNewswire Inc.Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) PatientsNASDAQ:BPTHBio Path Holdings Inc
15/04/202421:00GlobeNewswire Inc.Bio-Path Holdings Expands Global Patent PortfolioNASDAQ:BPTHBio Path Holdings Inc
02/04/202422:00GlobeNewswire Inc.Bio-Path Holdings Provides 2024 Clinical and Operational UpdateNASDAQ:BPTHBio Path Holdings Inc
11/03/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
09/03/202409:11Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:BPTHBio Path Holdings Inc
08/03/202423:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
08/03/202423:00GlobeNewswire Inc.Bio-Path Holdings Reports Full Year 2023 Financial ResultsNASDAQ:BPTHBio Path Holdings Inc
08/03/202422:22IH Market NewsU.S. Index Futures Fluctuate Ahead of Key Jobs Report; Oil Prices DipNASDAQ:BPTHBio Path Holdings Inc
08/03/202408:21Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BPTHBio Path Holdings Inc
01/03/202423:00GlobeNewswire Inc.Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024NASDAQ:BPTHBio Path Holdings Inc
29/02/202422:00Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:BPTHBio Path Holdings Inc
23/02/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
21/02/202423:00GlobeNewswire Inc.Bio-Path Holdings Announces 1-for-20 Reverse Stock SplitNASDAQ:BPTHBio Path Holdings Inc
03/02/202408:39Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BPTHBio Path Holdings Inc
03/02/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
24/01/202409:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
24/01/202408:51Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:BPTHBio Path Holdings Inc
18/01/202408:52Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:BPTHBio Path Holdings Inc
11/01/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
10/01/202423:00GlobeNewswire Inc.Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia PatientsNASDAQ:BPTHBio Path Holdings Inc
05/01/202409:18Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:BPTHBio Path Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:BPTH

Your Recent History

Delayed Upgrade Clock